Predictive Oncology Inc.
POAI
$1.06
-$0.03-2.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.66M | 1.36M | 1.69M | 1.91M | 1.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.66M | 1.36M | 1.69M | 1.91M | 1.73M |
| Cost of Revenue | 827.90K | 779.10K | 680.10K | 686.90K | 619.60K |
| Gross Profit | 827.80K | 584.60K | 1.01M | 1.22M | 1.11M |
| SG&A Expenses | 12.69M | 13.35M | 14.20M | 15.01M | 14.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.52M | 14.13M | 14.88M | 15.70M | 14.75M |
| Operating Income | -11.86M | -12.76M | -13.19M | -13.79M | -13.02M |
| Income Before Tax | -11.78M | -12.68M | -13.14M | -13.88M | -13.09M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.78 | -12.68 | -13.14 | -13.88 | -13.09 |
| Earnings from Discontinued Operations | -880.00K | -1.29M | -898.30K | -898.30K | -898.30K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.66M | -13.97M | -14.04M | -14.78M | -13.98M |
| EBIT | -11.86M | -12.76M | -13.19M | -13.79M | -13.02M |
| EBITDA | -11.46M | -12.36M | -12.66M | -13.25M | -12.40M |
| EPS Basic | -2.53 | -3.06 | -3.36 | -3.66 | -3.48 |
| Normalized Basic EPS | -1.49 | -1.77 | -1.96 | -2.12 | -2.01 |
| EPS Diluted | -2.53 | -3.06 | -3.36 | -3.66 | -3.48 |
| Normalized Diluted EPS | -1.49 | -1.77 | -1.96 | -2.12 | -2.01 |
| Average Basic Shares Outstanding | 21.80M | 19.19M | 16.82M | 16.15M | 16.06M |
| Average Diluted Shares Outstanding | 21.80M | 19.19M | 16.82M | 16.15M | 16.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |